Fredun Pharma

Why is Fredun Pharmaceuticals Ltd falling/rising?

As of 28-Jun, Fredun Pharmaceuticals Ltd's stock price is rising, currently at 2,689.55, reflecting a 4.17% increase. The stock has significantly outperformed the Sensex over various time frames, showing strong bullish trends despite a slight decrease in investor participation.

As of 28-Jun, Fredun Pharmaceuticals Ltd's stock price is rising, currently at 2,689.55, which reflects an increase of 107.65 or 4.17%. This upward movement is supported by several key factors. Over the past week, the stock has gained 2.83%, significantly outperforming the Sensex, which has declined by 0.40%. In the last month, the stock has risen by 12.81%, while the Sensex has only increased by 0.80%. Year-to-date, Fredun Pharmaceuticals has shown an impressive gain of 70.41%, contrasting sharply with the Sensex's decline of 9.53%. <BR><BR>The stock is also close to its 52-week high, being just 0.35% away from Rs 2,699. Today, it opened with a gap up of 2.2% and reached an intraday high of Rs 2,698, marking a 4.5% increase. Additionally, the stock has been on a consecutive gain streak for the last two days, accumulating a total return of 7.78% during this period. <BR><BR>Moreover, Fredun Pharmaceuticals is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend. However, it is worth noting that there has been a decrease in investor participation, with delivery volume falling by 12.95% against the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that the positive momentum is still robust. Overall, the combination of strong performance metrics and positive price movements contributes to the rising stock price of Fredun Pharmaceuticals Ltd.

Which are the latest news on Fredun Pharma?

What does Fredun Pharma do?

Fredun Pharmaceuticals Ltd, a Micro Cap company established in 1987, operates in the Pharmaceuticals & Biotechnology sector, reporting net sales of 210 Cr and a net profit of 11 Cr for the quarter ending March 2026. The company has a market cap of INR 1,307 Cr and key financial metrics include a P/E ratio of 34.00 and a dividend yield of 0.03%.

Overview:<BR>Fredun Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals was converted into a public limited company in March 1994. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 210 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 11 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 1,307 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 34.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.03% <BR>Debt Equity: 0.56 <BR>Return on Equity: 13.65% <BR>Price to Book: 4.57 <BR><BR>Contact Details:<BR>Address: 26 Manoj Industrial Premises, G D Ambedkar Marg Wadala Mumbai Maharashtra : 400031 <BR>Tel: 91-22-40318111 <BR>Email: business@fredungroup.com <BR>Website: http://www.fredungroup.com

How big is Fredun Pharma?

As of 10th June, Fredun Pharmaceuticals Ltd has a market capitalization of 1,307.00 Cr, with recent net sales of 593.49 Cr and a net profit of 32.68 Cr.

As of 10th June, Fredun Pharmaceuticals Ltd has a market capitalization of 1,307.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 593.49 Cr and a Net Profit of 32.68 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 141.38 Cr and Total Assets of 487.41 Cr.

Who are in the management team of Fredun Pharma?

The management team of Fredun Pharma includes Daulat N Medhora (Chairperson & Joint Managing Director), Nariman B Medhora (Executive Director), Fredun N Medhora (Managing Director & CFO), and several independent directors, along with the Company Secretary, Jinkal Shah, and Additional Director, Daisy Dsouza. They are responsible for guiding the company's strategic direction and operations.

The management team of Fredun Pharma includes the following key members:<BR><BR>1. **Daulat N Medhora** - Chairperson & Joint Managing Director<BR>2. **Nariman B Medhora** - Executive Director<BR>3. **Aspi N Raimalwala** - Non-Executive & Independent Director<BR>4. **Fredun N Medhora** - Managing Director & Chief Financial Officer<BR>5. **Rohinton Kanga** - Non-Executive & Independent Director<BR>6. **Jinkal Shah** - Company Secretary & Compliance Officer<BR>7. **Daisy Dsouza** - Additional Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Fredun Pharma?

Fredun Pharma's peers include Ind-Swift Labs, Shukra Pharma, Jagsonpal Pharma, Syncom Formul, Lincoln Pharma, Bajaj Healthcare, Fermenta Biotec, Themis Medicare, Wanbury, and Accent Microcell. Fredun Pharma has a strong growth rate and a 1-year return of 211.49%, outperforming many peers, while Shukra Pharma leads in management risk and capital structure.

Peers: The peers of Fredun Pharma are Ind-Swift Labs., Shukra Pharma., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Wanbury, and Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shukra Pharma, while Average management risk is found at Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Wanbury, and Accent Microcell. Growth is Excellent at Shukra Pharma and Fredun Pharma, while Below Average growth is noted at Ind-Swift Labs., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and Wanbury. Capital Structure is Excellent at Shukra Pharma, Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, and Accent Microcell, while Below Average capital structure is seen at Ind-Swift Labs., Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and Wanbury.<BR><BR>Return Snapshot: Shukra Pharma has the highest 1-year return at 114.16%, while Bajaj Healthcare has the lowest at -44.41%. Fredun Pharma's 1-year return of 211.49% is significantly higher than both. Additionally, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and Wanbury all have negative six-month returns.

Should I buy, sell or hold Fredun Pharmaceuticals Ltd?

Are Fredun Pharmaceuticals Ltd latest results good or bad?

Fredun Pharmaceuticals Ltd's latest Q3 FY26 results are positive, with a net profit of ₹10.48 crores (up 11.13% QoQ) and revenue of ₹160.93 crores (up 10.76% QoQ), marking their best quarterly performance. The stock rose 9.02% post-announcement, reflecting strong investor confidence in the company's growth and operational efficiency.

Fredun Pharmaceuticals Ltd's latest results for Q3 FY26 are quite positive. The company reported a net profit of ₹10.48 crores, which is an 11.13% increase quarter-over-quarter. Revenue also saw a significant rise, reaching ₹160.93 crores, up by 10.76% from the previous quarter. This marks the company's best quarterly performance in terms of revenue.<BR><BR>Additionally, the operating margin improved to 16.47%, reflecting effective cost management and operational efficiency. Although the PAT margin remained stable at 6.55%, the overall financial performance indicates strong growth momentum, especially considering that the nine-month revenue for FY2026 has already surpassed 82% of the total sales for FY2024.<BR><BR>The stock's surge of 9.02% following the results announcement further underscores investor confidence in the company's operational trajectory. Overall, the results suggest a robust performance, highlighting Fredun Pharmaceuticals' ability to grow profitably while managing its operational costs effectively.

How has been the historical performance of Fredun Pharma?

Fredun Pharma has shown steady growth, with net sales of 456.27 crore and a profit after tax of 19.74 crore for the fiscal year ending March 2025. The company's total assets increased to 307.60 crore, reflecting a solid financial position and consistent growth in sales and profits.

Answer:<BR>The historical performance of Fredun Pharma reflects a steady growth trajectory in various financial metrics.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Fredun Pharma reported net sales of 456.27 crore, resulting in a total operating income of the same amount. The total expenditure, excluding depreciation, was 401.36 crore, leading to an operating profit (PBDIT) of 54.91 crore, which corresponds to an operating profit margin of 12.16%. The profit before tax stood at 27.49 crore, with a profit after tax of 19.74 crore, yielding a PAT margin of 4.37%. The earnings per share (EPS) were reported at 41.82, while the diluted EPS was slightly higher at 44.83. On the balance sheet, total assets increased to 307.60 crore in March 2024 from 257.28 crore in the previous year, with total liabilities also rising to 105.51 crore. The book value per share adjusted to 255.15, indicating a solid increase from prior years. Cash flow analysis shows a net cash outflow of 2.00 crore for March 2024, with cash and cash equivalents closing at 1.00 crore. Overall, Fredun Pharma demonstrates a robust financial position with consistent growth in sales, profits, and asset values over the years.

Is Fredun Pharma overvalued or undervalued?

As of November 10, 2025, Fredun Pharma is considered overvalued with a PE ratio of 26.61, an EV to EBITDA of 13.28, and a ROE of 20.44%, despite outperforming the Sensex with a year-to-date return of 120.94%.

As of 10 November 2025, Fredun Pharma's valuation grade has moved from attractive to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 26.61, an EV to EBITDA of 13.28, and a ROE of 20.44%. <BR><BR>In comparison to its peers, Fredun Pharma's PE ratio is lower than Sun Pharma's 35.15 but significantly higher than Cipla's 22.45, suggesting that while it is less expensive than some competitors, it remains on the higher end of the spectrum. Additionally, the company's recent stock performance has outpaced the Sensex, with a year-to-date return of 120.94% compared to the Sensex's 6.91%, reinforcing the notion of overvaluation amidst strong market enthusiasm.

When is the next results date for Fredun Pharma?

The next results date for Fredun Pharma is 08 November 2025.

The next results date for Fredun Pharma is scheduled for 08 November 2025.

Who are the top shareholders of the Fredun Pharma?

The top shareholders of Fredun Pharma are Daulat Nariman Medhora with 29.88%, followed by Nikhil Kishorchandra Vora at 6.38%. Individual investors collectively own 44.5%, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Fredun Pharma include Daulat Nariman Medhora, who holds the largest stake at 29.88%. Following him, the highest public shareholder is Nikhil Kishorchandra Vora, with a holding of 6.38%. Additionally, individual investors collectively own 44.5% of the company. There are no institutional holdings or pledged promoter shares reported.

What is the technical trend for Fredun Pharma?

As of April 15, 2025, Fredun Pharma's technical trend is mildly bearish, with weekly indicators showing some positive momentum while daily moving averages and monthly indicators remain bearish.

As of 15 April 2025, the technical trend for Fredun Pharma has changed from bearish to mildly bearish. The weekly MACD and KST are both mildly bullish, suggesting some positive momentum, while the monthly indicators remain bearish. The daily moving averages indicate a mildly bearish stance, which is a counterpoint to the weekly signals. The Bollinger Bands show a mildly bullish trend on the weekly timeframe but are bearish on the monthly. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this outlook.

Has Fredun Pharma declared dividend?

Yes, Fredun Pharmaceuticals Ltd has declared a 7% dividend, with an ex-date of September 23, 2024. While recent total returns have been negative over shorter periods, the company has shown significant positive returns over the longer term.

Fredun Pharmaceuticals Ltd has declared a 7% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 7%<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.1%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -5.58%, with a dividend return of 0%, resulting in a total return of -5.58%.<BR><BR>Over the past year, the price return was -8.86%, the dividend return was 0.09%, leading to a total return of -8.77%.<BR><BR>In the 2-year period, the price return was -12.9%, with a dividend return of 0.16%, culminating in a total return of -12.74%.<BR><BR>For the 3-year period, the price return was -14.32%, the dividend return was 0.18%, resulting in a total return of -14.14%.<BR><BR>In the last 4 years, the price return was 71.47%, with a dividend return of 0.51%, giving a total return of 71.98%.<BR><BR>Over the past 5 years, the price return was 296.33%, and the dividend return was 1.12%, leading to a total return of 297.45%.<BR><BR>Overall, while Fredun Pharma has declared a dividend, the total returns over various periods show a mix of negative returns in the shorter terms and significant positive returns in the longer terms, indicating volatility and potential recovery in the company's performance.